President Donald Trump signed an executive order on 10 August 2026 directing federal officials to break up the combined measles, mumps and rubella (MMR) jab into three separate shots, but the Trump MMR vaccine order is already drawing sharp resistance from drug companies and former regulators who say meaningful change is years away, if it comes at all.
What the Trump MMR Vaccine Order Actually Requires
The order instructs federal officials to draw up plans within 90 days for separating the MMR shot and spacing out other childhood vaccines. However, the three individual vaccines it envisions are not currently licensed in the United States and have not been approved by the CIDRAP (University of Minnesota), which would require a lengthy regulatory process.
There are no individual vaccines approved by the Food and Drug Administration (FDA) for measles, mumps or rubella. The three-in-one combination shot has been the US standard since the early 1970s.
Pharmaceutical scientists and former regulators say the changes would likely take years and require drugmakers to spend tens of millions of dollars on new studies and manufacturing facilities.
Dr Jesse Goodman, a former FDA vaccine chief now a professor at Georgetown University, said companies would have to conduct large studies showing new individual shots produced immune responses in children comparable to the current combined version. The FDA would also have to review and licence each unbundled vaccine separately, a process Goodman described as without precedent.
‘I don’t think there’s any comparable example of removing hugely effective public health measures that protect babies for no documented scientific reason,’ he said.
Designing, constructing and winning federal approval for new vaccine plants typically takes about five years, according to industry experts. Individual measles shots have not been widely produced in the US for roughly a half-century.
Industry Shows No Sign of Compliance
Neither the White House nor the FDA can compel drugmakers to develop and seek approval for new vaccines. Merck and GSK, two of the main suppliers of US childhood vaccines, both said they stand by the safety and effectiveness of their existing products. Neither discussed plans to separate their shots.
‘To date, there has been no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots,’ Merck said in a statement.
Dr Paul Offit, a vaccine researcher at Children’s Hospital of Philadelphia and former government adviser, said companies have little commercial incentive to develop individual versions of vaccines they already sell as combinations.
‘They’d be competing against themselves, and there’s no reason to do that,’ Offit said.
Individual shots for measles and related diseases are used mainly by lower-income countries that cannot afford the MMR combination.
More Visits, Fewer Vaccinations
The MMR shot is currently given in two doses: the first at around age one, the second after age four. Splitting it into three separate components would require six office visits. Factoring in spacing for pertussis and other vaccines could multiply that number further.
Dr Anna Durbin said the practical effect would be fewer children vaccinated. ‘It’s going to be less convenient, more expensive and you’re going to have fewer people getting vaccinated,’ she said.
White House spokesman Kush Desai said the administration’s approach ‘will give parents more options on timing and frequency for their children, which ultimately will increase vaccination rates for all three diseases.’
The order is not legally binding on states. Only state governments have the authority to require vaccinations for schoolchildren. The order advises states to consider updating their laws to reflect the administration’s approach.
Offit said he expects states to disregard it. ‘I think states will ignore this,’ he said.
Federal officials must deliver their plans within the 90-day window set by the order, a deadline that will arrive well before any new vaccine could clear regulatory review.
